Brown Advisory’s Alto Neuroscience ANRO Stock Holding History

Brown Advisory’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$660K	Hold	25,000	–	–	﹤0.01%	1052
2026 Q1	$562K	Hold	25,000	–	–	﹤0.01%	1020
2025 Q4	$445K	Hold	25,000	–	–	﹤0.01%	1097
2025 Q3	$101K	Hold	25,000	–	–	﹤0.01%	1357
2025 Q2	$55K	Hold	25,000	–	–	﹤0.01%	1341
2025 Q1	$54K	Hold	25,000	–	–	﹤0.01%	1309
2024 Q4	$106K	Buy	+25,000	New	+$156K	﹤0.01%	1311

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Brown Advisory's ANRO Position: Q2 2026 in Review

Brown Advisory held its Alto Neuroscience (ANRO) position steady in Q2 2026 at 25,000 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

Brown Advisory first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Brown Advisory held 25,000 shares of Alto Neuroscience worth $660K as of Q2 2026.
Brown Advisory left its Alto Neuroscience share count unchanged in Q2 2026.
Alto Neuroscience made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1052 holding.
Brown Advisory first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.